Cellectis (CLLS) Expected to Release Quarterly Earnings on Thursday

Cellectis (NASDAQ:CLLS) is projected to post its H1 2026 results after the market closes on Thursday, August 6th. Analysts expect Cellectis to post earnings of ($0.2630) per share and revenue of $11.05 million for the quarter. Investors can check the company’s upcoming H1 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 11:40 AM ET.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.08. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.04 million. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.

Cellectis Trading Up 5.1%

CLLS stock traded up $0.14 during mid-day trading on Tuesday, reaching $2.89. The company’s stock had a trading volume of 8,768 shares, compared to its average volume of 37,655. The company has a market cap of $290.08 million, a price-to-earnings ratio of -4.31 and a beta of 2.91. Cellectis has a 12 month low of $2.48 and a 12 month high of $5.48. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 1.13. The business’s 50 day moving average price is $3.02 and its 200 day moving average price is $3.51.

Institutional Investors Weigh In On Cellectis

Institutional investors and hedge funds have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after buying an additional 3,284,409 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Cellectis during the 4th quarter worth approximately $15,385,000. Citadel Advisors LLC purchased a new position in shares of Cellectis in the third quarter worth $633,000. Marshall Wace LLP increased its position in shares of Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after acquiring an additional 168,038 shares during the period. Finally, Millennium Management LLC raised its position in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Citizens Jmp reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a research note on Tuesday, April 14th. Barclays initiated coverage on Cellectis in a research note on Thursday, May 28th. They set an “overweight” rating and a $9.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.00.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.